Abcellera Biologics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
AbCellera Biologics Inc. reported a 161% revenue increase and reduced net loss in 2025, driven by a patent settlement and clinical pipeline advancements.
NASDAQ
AbCellera Biologics Inc. files its annual report on Form 10-K, highlighting its focus on antibody drug discovery and development, advancements in its internal programs, and strategic partnerships.
NASDAQ
AbCellera Biologics Inc.'s 2023 annual report details strategic investments in technology and internal programs, alongside a diversified partnership portfolio, while navigating a shift from COVID-19 related revenues.